Evaluating the Suitability of 3D Bioprinted Samples for Experimental Radiotherapy: A Pilot Study.

3D bioprinting DNA damage experimental radiotherapy gammaH2AX high dose rate radiotherapy human lung cancer cells microbeam radiotherapy (MRT)

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
01 Sep 2022
Historique:
received: 05 08 2022
revised: 29 08 2022
accepted: 29 08 2022
entrez: 9 9 2022
pubmed: 10 9 2022
medline: 14 9 2022
Statut: epublish

Résumé

Radiotherapy is an important component in the treatment of lung cancer, one of the most common cancers worldwide, frequently resulting in death within only a few years of diagnosis. In order to evaluate new therapeutic approaches and compare their efficiency with regard to tumour control at a pre-clinical stage, it is important to develop standardized samples which can serve as inter-institutional outcome controls, independent of differences in local technical parameters or specific techniques. Recent developments in 3D bioprinting techniques could provide a sophisticated solution to this challenge. We have conducted a pilot project to evaluate the suitability of standardized samples generated from 3D printed human lung cancer cells in radiotherapy studies. The samples were irradiated at high dose rates using both broad beam and microbeam techniques. We found the 3D printed constructs to be sufficiently mechanically stable for use in microbeam studies with peak doses up to 400 Gy to test for cytotoxicity, DNA damage, and cancer cell death in vitro. The results of this study show how 3D structures generated from human lung cancer cells in an additive printing process can be used to study the effects of radiotherapy in a standardized manner.

Identifiants

pubmed: 36077349
pii: ijms23179951
doi: 10.3390/ijms23179951
pmc: PMC9456381
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : SCHU 2589/7-1
Organisme : PETRA III
ID : no grant number

Références

Int J Bioprint. 2021 Apr 9;7(2):332
pubmed: 33997432
Sci Rep. 2019 Feb 14;9(1):2103
pubmed: 30765760
Cureus. 2021 Nov 6;13(11):e19317
pubmed: 35223216
Sci Transl Med. 2014 Jul 16;6(245):245ra93
pubmed: 25031268
Br J Radiol. 2017 Oct;90(1078):20170073
pubmed: 28749174
Dev Med Child Neurol. 2007 Aug;49(8):577-81
pubmed: 17635201
J Med Radiat Sci. 2018 Sep;65(3):171-172
pubmed: 30175453
Biofabrication. 2010 Mar;2(1):010201
pubmed: 20811115
Cancer Commun (Lond). 2021 Dec;41(12):1331-1353
pubmed: 34713636
3 Biotech. 2018 Dec;8(12):501
pubmed: 30498674
Am J Transl Res. 2014 Jan 15;6(2):114-8
pubmed: 24489990
Int J Biol Macromol. 2022 May 15;207:278-288
pubmed: 35257733
RNA Biol. 2019 Nov;16(11):1622-1632
pubmed: 31387452
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Toxicol Rep. 2020 Nov 21;7:1578-1587
pubmed: 33304827
Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):360-369
pubmed: 32088292
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Physiology (Bethesda). 2017 Jul;32(4):266-277
pubmed: 28615311
J Funct Biomater. 2018 Mar 01;9(1):
pubmed: 29494503
J Synchrotron Radiat. 2011 Jul;18(Pt 4):630-6
pubmed: 21685681
Front Bioeng Biotechnol. 2022 Jun 09;10:895842
pubmed: 35757809
Essays Biochem. 2021 Aug 10;65(3):417-427
pubmed: 34328185
ACS Appl Mater Interfaces. 2021 Jun 9;13(22):25611-25623
pubmed: 34038086
Adv Sci (Weinh). 2021 Mar 08;8(10):2004990
pubmed: 34026463
ACS Appl Mater Interfaces. 2020 Oct 7;12(40):44563-44577
pubmed: 32966746
ACS Appl Mater Interfaces. 2022 Jul 13;14(27):30455-30465
pubmed: 35777738
Int J Radiat Oncol Biol Phys. 2021 Jun 1;110(2):521-525
pubmed: 33383127
Int J Mol Sci. 2021 Dec 23;23(1):
pubmed: 35008547
Cells. 2021 Jun 18;10(6):
pubmed: 34207111
Sci Rep. 2018 Sep 17;8(1):13877
pubmed: 30224659
Int J Mol Sci. 2022 Mar 22;23(7):
pubmed: 35408789
Int J Radiat Oncol Biol Phys. 2021 Dec 1;111(5):1276-1288
pubmed: 34364976
Int J Cancer. 1998 Nov 23;78(5):654-60
pubmed: 9808538
Cell Res. 2020 Oct;30(10):833-853
pubmed: 32499560
Regen Med. 2018 Jan;13(1):73-87
pubmed: 29350587

Auteurs

Munir A Al-Zeer (MA)

Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany.

Franziska Prehn (F)

Department of Radiooncology, Rostock University Medical Center, 18059 Rostock, Germany.

Stefan Fiedler (S)

European Molecular Biology Laboratory (EMBL), Hamburg Outstation/DESY, 22607 Hamburg, Germany.

Ulrich Lienert (U)

PETRA III/DESY, Beamline P21.2, 22607 Hamburg, Germany.

Michael Krisch (M)

European Synchrotron Radiation Facility (ESRF), 38043 Grenoble, France.

Johanna Berg (J)

Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany.

Jens Kurreck (J)

Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany.

Guido Hildebrandt (G)

Department of Radiooncology, Rostock University Medical Center, 18059 Rostock, Germany.

Elisabeth Schültke (E)

Department of Radiooncology, Rostock University Medical Center, 18059 Rostock, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH